Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers

Autor: Youlia M. Kirova, Piotr J. Wysocki, Judy W. C. Ho, Ute Hamann, Dominique Stoppa-Lyonnet, Fernando Schmitt, Gulnur Guler, Zheng Shu, Neva E. Haites, Peter Simmonds, Cornelis J.M. Lips, Janis Gardovskis, Alain Fourquet, Evangelia Razis, Jean-Yves Pierga, Johannes W. B. de Groot, Siniša Radulović, Kay Huebner, Diana Eccles, Lidia Larizza, Åke Borg, Niklas Loman, Thangarajan Rajkumar, Peter T. Silberstein, Rita K. Schmutzler, Arvids Irmejs, Håkan Olsson, Rolf H. Sijmons, Lenka Foretova, Evgeny N. Imyanitov, Winette T. A. van der Graaf, Henry T. Lynch, Pål Møller, Pax H.B. Willemse, Pavel Elsakov, Vladimir Zajac, Jae-Gahb Park, Jacob Smeltzer, Walter P. Weber, P. Goetz, Mira Brankovic-Magic, Marianna Bitina, Gunta Purkalne, Andris Gardovskis, Drakoulis Yannoukakos
Jazyk: angličtina
Rok vydání: 2007
Předmět:
Oncology
HEREDITARY BREAST
medicine.medical_specialty
endocrine system diseases
OVARIAN-CANCER
MISMATCH REPAIR
03 medical and health sciences
0302 clinical medicine
Germline mutation
Breast cancer
MICROSATELLITE-INSTABILITY
Internal medicine
medicine
CELL-CYCLE CHECKPOINT
skin and connective tissue diseases
GeneralLiterature_REFERENCE(e.g.
dictionaries
encyclopedias
glossaries)
Genetics (clinical)
030304 developmental biology
0303 health sciences
business.industry
Microsatellite instability
Cancer
PREOPERATIVE CHEMOTHERAPY
Retrospective cohort study
NONPOLYPOSIS COLORECTAL-CANCER
PREDICTS FAVORABLE RESPONSE
medicine.disease
3. Good health
Natural history
030220 oncology & carcinogenesis
GENE-EXPRESSION PROFILES
Mutation (genetic algorithm)
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Commentary
Ovarian cancer
business
MESSENGER-RNA
Zdroj: Hereditary Cancer in Clinical Practice
Hereditary cancer in clinical practice, 5(3), 119-143. BioMed Central Ltd.
ISSN: 1897-4287
1731-2302
Popis: BRCA1-associated cancers differ from non-hereditary cancers for many factors, including somatic mutation. It can be a subject of discussion that the natural history and response to treatment also may differ between the hereditary and sporadic subgroups. Three frequent BRCA1 mutations (5382insC, 4153delA, C61G) in the Baltic countries (Lithuania, Latvia, Byelorussia and Poland) open a way for the chip test to select a subgroup from women with breast cancer. These women with BRCA1 breast cancer have a chance to get adequate treatment, including neo-adjuvant chemotherapy. So far many retrospective studies of survival, that used the same gold standard treatment for women with BRCA1 breast cancer and for women without a mutation, have not found a difference between these groups. Some studies show a worse survival result in women with a BRCA1 mutation than women without the mutation.
Databáze: OpenAIRE
Externí odkaz: